A groundbreaking international study has identified 300 previously unknown genetic links to depression, marking a significant leap forward in understanding this widespread mental health condition.
The research, led by scientists from the University of Edinburgh and King’s College London, analyzed genetic data from over five million people across 29 countries, making it the largest and most diverse genetic study on depression to date.
The study revealed a total of 700 variations in the genetic code associated with depression risk, with nearly 300 of these being newly discovered. Importantly, the research included participants from diverse ethnic backgrounds, with one in four coming from non-European ancestries.
This inclusive approach allowed researchers to identify genetic risk factors for depression across all major global populations for the first time. The findings have significant implications for the development of more targeted and effective treatments for depression.
The research team highlighted two existing drugs, pregabalin (used for chronic pain) and modafinil (used for narcolepsy), as potential candidates for repurposing to treat depression. However, they cautioned that further studies and clinical trials are necessary to explore these possibilities.
Professor Andrew McIntosh from the University of Edinburgh emphasized the need for larger and more globally representative studies to provide insights for developing new and better therapies.
Genetic Breakthrough: 300 New Links to Depression Uncovered
This research opens up new avenues for translating genetic discoveries into improved care for people with depression, potentially benefiting millions worldwide affected by this prevalent and debilitating condition.
The study’s results underscore the complex, polygenic nature of depression, where multiple genes contribute to its development. Each genetic variant has a small effect on overall risk, but when combined, they can significantly increase an individual’s susceptibility to depression.
This knowledge could lead to more personalized approaches in diagnosing and treating depression in the future.
This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error · Editorial responsibility: Matthias Camenzind, Editor-in-Chief